HeartBeam 5/13/2026 Earnings Report

HeartBeam EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.14
• Beat/Miss: N/A
• One Year Ago EPS: N/A

HeartBeam Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.15 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

HeartBeam Announcement Details

• Date: 5/13/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

HeartBeam (NASDAQ:BEATW) is a clinical-stage medical technology company focused on transforming the diagnosis of acute cardiac events through innovative electrocardiogram (ECG) solutions. The company’s core offering leverages proprietary VectorBEAM™ technology to reconstruct a full 12-lead ECG from a compact, three-lead wearable or handheld device. By enabling rapid acquisition and secure transmission of high-fidelity ECG data, HeartBeam’s approach aims to expedite the detection of myocardial ischemia in out-of-hospital settings.

HeartBeam’s product ecosystem combines hardware, mobile applications, and cloud-based analytics. The wearable or handheld form factor is designed for use by patients, first responders, and telehealth providers, facilitating real-time triage and remote consultation with cardiovascular specialists. The accompanying software platform supports automated comparisons of current readings against patient-specific baseline ECGs, enhancing the accuracy of ischemia detection and reducing reliance on subjective interpretation.

Based in Santa Monica, California, HeartBeam is conducting clinical studies to validate its technology in collaboration with leading medical centers and emergency medical services organizations across the United States. The company’s regulatory strategy has included submissions to the U.S. Food and Drug Administration and engagements with European health authorities in anticipation of broader market access. HeartBeam’s leadership team combines experience in medical device development, cardiovascular clinical research, and digital health commercialization, positioning the company to address critical gaps in early heart attack diagnosis and remote patient monitoring.